Hutchmed (China) Limited

Director's Dealing • Mar 8, 2023

National Storage Mechanism | Additional information

RNS Number : 2733S

Hutchmed (China) Limited

08 March 2023

Director's Share Dealing

Hong Kong, Shanghai & Florham Park, NJ - Wednesday, March 8, 2023: HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM: HCM; SEHK:13) has received notifications that Mr Johnny Cheng, Executive Director and Chief Financial Officer, sold a total of 1,300,000 Ordinary Shares of US$0.10 each of the Company at an average price of HK$27.073 per Ordinary Shares on March 3, 2023  and March 6, 2023.

Following the above sale of 1,300,000 Ordinary Shares, the holding of Mr Cheng is 1,261,460 Ordinary Shares and 274,493 ADSs Note, representing approximately 0.3% of the current issued share capital of the Company.

Note: 274,493 ADSs included (i) 41,552 ADSs currently held by Mr Cheng, (ii) 217,800 ADSs granted under Share Option Scheme and (iii) 15,141 ADSs as beneficiary of a trust under long term incentive plan.

The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Mr Johnny Cheng

2

Reason for the notification

a)

Position/status

Executive Director and Chief Financial Officer

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

HUTCHMED (China) Limited

b)

LEI

2138006X34YDQ6OBYE79

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of US$0.10 each

DI ISIN: KYG4672N1198

b)

Nature of the transaction

Sale of 830,000 Ordinary Shares on March 3, 2023 at an average price of HK$27.101.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

HK$26.850

50,000 Ordinary Shares

HK$26.950

20,000 Ordinary Shares

HK$27.000

110,000 Ordinary Shares

HK$27.005

50,000 Ordinary Shares

HK$27.015

20,000 Ordinary Shares

HK$27.016

40,000 Ordinary Shares

HK$27.027

30,000 Ordinary Shares

HK$27.050

10,000 Ordinary Shares

HK$27.091

200,000 Ordinary Shares

HK$27.100

50,000 Ordinary Shares

HK$27.113

100,000 Ordinary Shares

HK$27.150

20,000 Ordinary Shares

HK$27.200

30,000 Ordinary Shares

HK$27.300

40,000 Ordinary Shares

HK$27.450

10,000 Ordinary Shares

HK$27.500

20,000 Ordinary Shares

HK$27.656

20,000 Ordinary Shares

HK$27.700

10,000 Ordinary Shares

d)

Aggregated information

-	Aggregated volume
-	Price

Aggregated volume: 830,000 Ordinary Shares

Price information: HK$22,494,120

e)

Date of the transaction

2023-03-03

f)

Place of the transaction

Hong Kong Stock Exchange

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of US$0.10 each

DI ISIN: KYG4672N1198

b)

Nature of the transaction

Sale of 470,000 Ordinary Shares on March 6, 2023 at an average price of HK$27.022.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

HK$26.850

30,000 Ordinary Shares

HK$26.900

10,000 Ordinary Shares

HK$26.908

10,000 Ordinary Shares

HK$26.950

70,000 Ordinary Shares

HK$27.000

50,000 Ordinary Shares

HK$27.050

68,500 Ordinary Shares

HK$27.060

200,000 Ordinary Shares

HK$27.100

20,000 Ordinary Shares

HK$27.250

10,000 Ordinary Shares

HK$27.300

1,500 Ordinary Shares

d)

Aggregated information

-	Aggregated volume
-	Price

Aggregated volume: 470,000 Ordinary Shares

Price information: HK$12,700,455

e)

Date of the transaction

2023-03-06

f)

Place of the transaction

Hong Kong Stock Exchange

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has more than 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception, HUTCHMED has focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: www.hutch‑med.com or follow us on LinkedIn.

Contacts

##### Investor Enquiries
Mark Lee, Senior Vice President	+852 2121 8200
Annie Cheng, Vice President	+1 (973) 306 4490
##### Media Enquiries
Americas - Brad Miles, Solebury Trout	+1 (917) 570 7340 (Mobile)  [email protected]
Europe - Ben Atwell / Alex Shaw, FTI Consulting	+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) [email protected]
Asia - Zhou Yi, Brunswick	+852 9783 6894 (Mobile) [email protected]
##### Nominated Advisor
Atholl Tweedie / Freddy Crossley, Panmure Gordon (UK) Limited	+44 (20) 7886 2500

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHNKFBDOBKKDNK